definium therapeutics reports promising phase iii results for LSD‑based depression drug
Definium Therapeutics reports that a single 100 µg dose of its LSD‑based drug DT120 cut depression scores by 8.1 points versus placebo in a 149‑patient phase III trial, and the firm is seeking FDA breakthrough‑therapy…
